Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4
Source: Targeted Oncology, July 2024
During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the first article of a 2-part series.
Targeted Oncology: Why is it valuable to indirectly compare the experimental arms of the RELATIVITY-047 (NCT03470922) and CheckMate 067 (NCT01844505) trials of patients with metastatic melanoma?
MICHAEL POSTOW, MD: We now know nivolumab/relatlimab [Opdualag] is 10% better than nivolumab [Opdivo] alone; that’s a loose 10% based upon [overall response rate (ORR) and progression-free survival (PFS)].1 But ipilimumab [Yervoy] plus nivolumab also looks better than nivolumab monotherapy. So how do we think about 1 combination vs the other in terms of efficacy with the cross-trial comparisons?